Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 11:30 | 2026-06-01 | MDWD | MediWound Ltd. | Fox David Morton | Director | Medicinal Chemicals & Botanical Products | BUY | $14.11 | 3,537 | $49,901 | 22,283 | +18.9% |
| 2026-06-02 11:00 | 2026-05-29 | KRRO | Korro Bio, Inc. | Aiyar Ram | Director, Officer; President and CEO | Pharmaceutical Preparations | SALE | $12.98 | 15,152 | $196,673 | 74,848 | -16.8% |
| 2026-06-01 20:05 | 2026-05-29 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Officer; Chief Scientific Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $19.87 | 6,000 | $119,220 | 67,845 | -8.1% |
| 2026-06-01 20:36 | 2026-06-01 | USNA | USANA HEALTH SCIENCES INC | Fleming John Turman | Director | Medicinal Chemicals & Botanical Products | SALE | $17.93 | 2,450 | $43,929 | 4,230 | -36.7% |
| 2026-06-01 20:10 | 2026-05-29 | ASND | Ascendis Pharma A/S | SMITH SCOTT THOMAS | Officer; EVP & Chief Financial Officer | Pharmaceutical Preparations | BUY | $223.32 | 250 | $55,830 | 4,267 | +6.2% |
| 2026-06-01 20:05 | 2026-05-28 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $67.91 | 16,470 | $1,118,555 | 846,872 | -1.9% |
| 2026-06-01 20:05 | 2026-05-28 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Director | Biological Products, (No Diagnostic Substances) | SALE | $68.00 | 2,500 | $170,000 | 22,222 | -10.1% |
| 2026-06-01 20:05 | 2026-05-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $16.00 | 679 | $10,864 | 47,122 | -1.4% |
| 2026-06-01 20:25 | 2026-05-28 | PGEN | PRECIGEN, INC. | Sabzevari Helen | Officer; President and CEO | Pharmaceutical Preparations | SALE | $4.36 | 119,250 | $519,930 | 3,768,872 | -3.1% |
| 2026-06-01 20:06 | 2026-05-28 | JAZZ | Jazz Pharmaceuticals plc | Pearce Samantha | Officer; EVP, Chief Commercial Officer | Pharmaceutical Preparations | OPT+S | $235.41 | 6,907 | $1,625,977 | 50,272 | -12.1% |
| 2026-06-01 20:09 | 2026-05-28 | JAZZ | Jazz Pharmaceuticals plc | Patil Neena M | Officer; EVP & Chief Legal Officer | Pharmaceutical Preparations | SALE | $236.97 | 1,192 | $282,468 | 52,626 | -2.2% |
| 2026-06-01 20:11 | 2026-05-29 | ASND | Ascendis Pharma A/S | BIENAIME JEAN JACQUES | Director | Pharmaceutical Preparations | BUY | $223.12 | 500 | $111,562 | 900 | +125.0% |
| 2026-06-01 20:10 | 2026-05-28 | AIMD | Ainos, Inc. | chiang yao-chung | Director | Pharmaceutical Preparations | BUY | $2.30 | 250 | $575 | 5,779 | +4.5% |
| 2026-06-02 01:30 | 2026-05-28 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Ghiath M. | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.59 | 8,539,709 | $5,000,000 | 22,092,068 | +63.0% |
| 2026-06-02 01:13 | 2026-05-28 | QTTB | Q32 Bio Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | Pharmaceutical Preparations | BUY | $8.00 | 1,875,000 | $15,000,000 | 625,000 | +100.0% |
| 2026-06-02 01:15 | 2026-05-28 | QTTB | Q32 Bio Inc. | Xu Diyong | Director, 10% owner | Pharmaceutical Preparations | BUY | $8.00 | 1,875,000 | $15,000,000 | 625,000 | +100.0% |
| 2026-06-01 23:59 | 2026-05-28 | EVMN | Evommune, Inc. | Carver Kyle | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $22.84 | 18,175 | $415,117 | 59,335 | -23.4% |
| 2026-06-02 00:00 | 2026-05-28 | EVMN | Evommune, Inc. | Moss Gregory S. | Officer; Chief Business & Legal Officer | Pharmaceutical Preparations | OPT+S | $22.83 | 14,223 | $324,711 | 60,835 | -18.9% |
| 2026-06-01 23:49 | 2026-06-01 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Soergel David | Officer; Chief Medical Officer | Pharmaceutical Preparations | SALE | $495.74 | 1,042 | $516,561 | 10,033 | -9.4% |
| 2026-06-01 23:23 | 2026-06-01 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Officer; Chief Accounting Officer | Pharmaceutical Preparations | SALE | $25.77 | 2,562 | $66,024 | 39,581 | -6.1% |
| 2026-06-01 23:26 | 2026-06-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer; EVP R&D, Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $41.67 | 9,000 | $375,044 | 77,389 | -10.4% |
| 2026-06-01 23:11 | 2026-06-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $23.77 | 4,653 | $110,602 | 105,689 | -4.2% |
| 2026-06-01 22:51 | 2026-06-01 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer; EVP, Chief Commercial Officer | Pharmaceutical Preparations | OPT+S | $74.08 | 15,000 | $1,111,200 | 58,555 | -20.4% |
| 2026-06-01 22:54 | 2026-06-01 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | Pharmaceutical Preparations | SALE | $76.09 | 2,933 | $223,172 | 10,283 | -22.2% |
| 2026-06-01 22:49 | 2026-06-01 | CYTK | CYTOKINETICS INC | PARSHALL B LYNNE | Director | Pharmaceutical Preparations | SALE | $74.08 | 5,000 | $370,400 | 15,784 | -24.1% |
| 2026-06-01 22:31 | 2026-05-29 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | Pharmaceutical Preparations | OPT+S | $99.64 | 9,000 | $896,760 | 7,825 | -53.5% |
| 2026-06-01 22:08 | 2026-06-01 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer; Chief Scientific Officer | Pharmaceutical Preparations | SALE | $13.16 | 4,170 | $54,862 | 139,372 | -2.9% |
| 2026-06-01 21:35 | 2026-05-28 | KRRO | Korro Bio, Inc. | FORMELA JEAN FRANCOIS | Director | Pharmaceutical Preparations | SALE | $13.95 | 2,860 | $39,897 | 194,655 | -1.4% |
| 2026-06-01 21:35 | 2026-05-29 | CRSP | CRISPR Therapeutics AG | Patel Naimish | Officer; Chief Medical Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $55.62 | 3,786 | $210,577 | 19,357 | -16.4% |
| 2026-06-01 21:20 | 2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | 10% owner, Other | Pharmaceutical Preparations | SALE | $20.02 | 25,000 | $500,543 | 130,142 | -16.1% |
| 2026-06-01 21:21 | 2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian BioPharma Inc | 10% owner | Pharmaceutical Preparations | SALE | $20.02 | 25,000 | $500,543 | 130,142 | -16.1% |
| 2026-06-01 20:55 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer; Chief Administrative Officer | Pharmaceutical Preparations | BUY | $2.57 | 1,829 | $4,701 | 9,840 | +22.8% |
| 2026-06-01 20:56 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer; Chief Business - Strategy Off | Pharmaceutical Preparations | BUY | $2.57 | 1,582 | $4,066 | 9,176 | +20.8% |
| 2026-06-01 20:58 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $2.57 | 2,129 | $5,472 | 9,970 | +27.2% |
| 2026-06-01 20:59 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $2.57 | 2,292 | $5,890 | 10,758 | +27.1% |
| 2026-06-01 21:01 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer; Pres. Research & Development | Pharmaceutical Preparations | BUY | $2.57 | 1,786 | $4,590 | 17,131 | +11.6% |
| 2026-06-01 20:26 | 2026-05-28 | PGEN | PRECIGEN, INC. | Lehr Donald P. | Officer; Chief Legal Officer | Pharmaceutical Preparations | SALE | $4.36 | 29,131 | $127,011 | 755,461 | -3.7% |
| 2026-06-01 20:27 | 2026-05-28 | PGEN | PRECIGEN, INC. | Shah Rutul R | Officer; Chief Operating Officer | Pharmaceutical Preparations | SALE | $4.36 | 42,703 | $186,185 | 497,751 | -7.9% |
| 2026-06-01 20:28 | 2026-05-28 | PGEN | PRECIGEN, INC. | Tennant Phil | Officer; Chief Commercial Officer | Pharmaceutical Preparations | SALE | $4.36 | 30,272 | $131,986 | 139,369 | -17.8% |
| 2026-06-01 20:29 | 2026-05-28 | PGEN | PRECIGEN, INC. | Thomasian Harry Jr. | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $4.36 | 41,884 | $182,614 | 554,535 | -7.0% |
| 2026-06-01 20:30 | 2026-05-28 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer; Chief Legal Officer | Pharmaceutical Preparations | OPT+S | $107.84 | 5,500 | $593,101 | 59,634 | -8.4% |
| 2026-06-01 20:31 | 2026-05-29 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $553.83 | 9,500 | $5,261,365 | 40,513 | -19.0% |
| 2026-06-01 20:31 | 2026-05-28 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $107.80 | 5,500 | $592,923 | 58,117 | -8.6% |
| 2026-06-01 11:33 | 2026-05-29 | CMMB | Chemomab Therapeutics Ltd. | Mor George Adi | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $2.07 | 9,804 | $20,246 | 139,131 | +7.6% |
| 2026-06-01 11:00 | 2026-05-29 | MDWD | MediWound Ltd. | Rubinstein Samuel | Director | Medicinal Chemicals & Botanical Products | BUY | $14.33 | 150 | $2,150 | 2,993 | +5.3% |
| 2026-05-29 20:05 | 2025-09-17 | AWHL | Aspira Women's Health Inc. | cohen Jeffrey k | Director | In Vitro & In Vivo Diagnostic Substances | BUY | $0.45 | 55,556 | $25,000 | 374,906 | +17.4% |
| 2026-05-29 20:05 | 2025-09-17 | AWHL | Aspira Women's Health Inc. | Fraser John D | Director | In Vitro & In Vivo Diagnostic Substances | BUY | $0.45 | 16,389 | $7,375 | 566,393 | +3.0% |
| 2026-05-29 20:05 | 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer; CHIEF DEVELOPMENT OFFICER | Pharmaceutical Preparations | OPT+S | $26.78 | 33,800 | $905,225 | 229,918 | -12.8% |
| 2026-05-29 20:04 | 2026-05-28 | IMVT | Immunovant, Inc. | Fromkin Andrew J. | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $33.51 | 221,951 | $7,438,111 | 74,382 | -74.9% |
| 2026-05-29 20:37 | 2026-05-28 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $565.64 | 9,500 | $5,373,592 | 40,513 | -19.0% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.